Amiloride
Overview
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Amiloride</th>
</tr>
<tr>
<td class="label">Indication</td>
<td>Typical Dose</td>
</tr>
<tr>
<td class="label">Hypertension</td>
<td>5-10 mg daily</td>
</tr>
<tr>
<td class="label">Heart failure</td>
<td>5-10 mg daily</td>
</tr>
<tr>
<td class="label">Edema</td>
<td>5-10 mg daily</td>
</tr>
<tr>
<td class="label">Combination therapy</td>
<td>2.5-5 mg daily</td>
</tr>
<tr>
<td class="label">Oral bioavailability</td>
<td>50%</td>
</tr>
<tr>
<td class="label">Time to peak plasma</td>
<td>2-4 hours</td>
</tr>
<tr>
<td class="label">Protein binding</td>
<td>40%</td>
</tr>
<tr>
<td class="label">Volume of distribution</td>
<td>3-8 L/kg</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>6-9 hours</td>
</tr>
<tr>
<td class="label">Excretion</td>
<td>Renal (unchanged in urine)</td>
</tr>
<tr>
<td class="label">Dialysis</td>
<td>Not significantly removed</td>
</tr>
<tr>
<td class="label">CNS penetration</td>
<td>Limited; debated</td>
</tr>
<tr>
<td class="label">System</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Hyperkalemia</td>
<td>2-5%</td>
</tr>
<tr>
<td class="label">Headache</td>
<td>1-3%</td>
</tr>
<tr>
<td class="label">Fatigue</td>
<td>1-3%</td>
</tr>
<tr>
<td class="label">Nausea</td>
<td>1-2%</td>
</tr>
<tr>
<td class="label">Dry mouth</td>
<td>1-2%</td>
</tr>
<tr>
<td class="label">Interaction</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">ACE inhibitors</td>
<td>Increased hyperkalemia risk</td>
</tr>
<tr>
<td class="label">ARBs</td>
<td>Increased hyperkalemia risk</td>
</tr>
<tr>
<td class="label">Potassium supplements</td>
<td>Severe hyperkalemia</td>
</tr>
<tr>
<td class="label">Spironolactone</td>
<td>Severe hyperkalemia</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>Reduced lithium clearance</td>
</tr>
<tr>
<td class="label">NSAIDs</td>
<td>Reduced diuretic effect</td>
</tr>
<tr>
<td class="label">Digoxin</td>
<td>Possible interaction</td>
</tr>
<tr>
<td class="label">Condition</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>II</td>
</tr>
<tr>
<td class="label">Hypertension</td>
<td>IV</td>
</tr>
<tr>
<td class="label">Edema</td>
<td>IV</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Amiloride</td>
<td>ENaC/ASIC</td>
</tr>
<tr>
<td class="label">Riluzole</td>
<td>Glutamate release</td>
</tr>
<tr>
<td class="label">Edaravone</td>
<td>Oxidative stress</td>
</tr>
<tr>
<td class="label">Minocycline</td>
<td>Microglia</td>
</tr>
<tr>
<td class="label">Coenzyme Q10</td>
<td>Mitochondria</td>
</tr>
</table>
Amiloride is a potassium-sparing diuretic that blocks epithelial sodium channels (ENaC). Originally developed for cardiovascular indications including hypertension and heart failure, amiloride has attracted significant interest in neuroscience for its potential neuroprotective effects in neurodegenerative diseases. The drug's dual ability to block both ENaC and acid-sensing ion channels (ASICs) provides multiple mechanistic pathways that may confer protection against various forms of neuronal injury[@waldmann2016][@xiong2004].
The intersection of ion channel pharmacology and neurodegeneration research has revealed unexpected therapeutic potential for repositioned drugs like amiloride. While traditionally considered a renal-targeting medication, emerging evidence suggests that amiloride's effects on neuronal ion channels may provide meaningful neuroprotection in conditions ranging from amyotrophic lateral sclerosis (ALS) to Parkinson's disease (PD) and stroke[@benveniste2019][@brown2021].
Historical Context and Drug Development
Amiloride was first approved by the FDA in 1981 under the brand name Midamor, developed by Merck & Co. The drug was initially designed to address a specific clinical need: the management of hypertension and edema while avoiding the potassium loss associated with thiazide diuretics. Its mechanism of action on ENaC in the renal collecting duct was well-characterized, and the drug became a standard component of combination antihypertensive therapy[@baudier2021].
The serendipitous discovery of amiloride's effects on ASICs came later, when researchers investigating proton-gated ion channels recognized that amiloride served as a potent pharmacological tool to study these proteins. This finding opened new avenues of research into the role of ASICs in neurological disease, ultimately leading to investigations of amiloride's neuroprotective potential[@waldmann1995].
Mechanism of Action
Primary Pharmacology: ENaC Blockade
Amiloride's primary pharmacological action involves inhibition of epithelial sodium channels (ENaC) in the distal tubule and collecting duct of the kidney. ENaC is a heteromeric channel composed of three subunits (α, β, γ), and amiloride binds with high affinity to the pore-forming α subunit, blocking sodium ion flux[@garty1997].
The renal effects include:
- Sodium retention prevention: Reduces Na+ reabsorption in collecting ducts by 50-70%
- Potassium-sparing effect: Prevents potassium loss (opposite effect of thiazides)
- Diuretic action: Promotes water excretion without potassium loss
The clinical implications of ENaC blockade extend beyond the kidney, as these channels are also expressed in various tissues including the brain, lung, and colon. In the central nervous system, ENaC expression has been documented in the substantia nigra, hippocampus, and cortex, providing a mechanistic basis for potential central nervous system effects[@amin2005].
Neuroprotective Mechanisms
Amiloride exerts neuroprotective effects through multiple overlapping mechanisms:
1. Acid-Sensing Ion Channel (ASIC) Blockade
ASICs are proton-gated sodium channels belonging to the degenerin/epithelial sodium channel (DEG/ENaC) superfamily. These channels are activated by decreases in extracellular pH and are highly expressed in neurons throughout the brain and spinal cord[@krishtal1981].
ASIC1a is the most studied ASIC subunit in neurodegeneration:
- Expressed in hippocampal CA1 neurons, cortical pyramidal neurons, and motor neurons
- Activated by acidosis occurring during ischemia, seizures, and neuroinflammation
- mediates calcium influx that triggers excitotoxic cell death
- Amiloride blocks ASIC1a with IC50 ~10 μM, reducing calcium influx and neuronal death[@waldmann1997]
The ASIC1a channel represents a critical link between tissue acidosis and neuronal injury. In conditions such as stroke, traumatic brain injury, and neurodegenerative diseases, local pH drops significantly, leading to sustained ASIC activation. By blocking this pathway, amiloride may prevent the cascade of events leading to irreversible neuronal damage[@xiong2004a].
2. Reduced Excitotoxicity
Excitotoxicity mediated by glutamate receptors represents a common final pathway in many neurodegenerative conditions. Amiloride modulates this process through several mechanisms:
- NMDA receptor modulation: ENaC interacts with NMDA receptors, and amiloride may reduce excitotoxic signaling
- Voltage-gated calcium channel effects: Modulates calcium entry through multiple pathways
- Metabolic stabilization: Helps maintain ionic homeostasis under stressful conditions[@johnson2011]
The concept of "secondary excitotoxicity" — where acidosis exacerbates glutamate-induced neuronal death — provides a framework for understanding how ASIC blockade complements other neuroprotective strategies. In this model, acidosis and glutamate act synergistically to overwhelm neuronal calcium buffering capacity, and ASIC blockade interrupts this fatal synergy[@mccarthy2017].
3. Anti-Inflammatory Effects
Neuroinflammation is a hallmark of neurodegenerative diseases, and amiloride exhibits anti-inflammatory properties relevant to this context:
- Microglial activation modulation: Reduces pro-inflammatory cytokine production
- NF-κB pathway effects: Inhibits key inflammatory signaling cascades
- TNF-α reduction: Decreases levels of this critical inflammatory mediator
These effects may be particularly relevant in conditions such as Alzheimer's disease, where microglial activation contributes to disease progression, and in Parkinson's disease, where neuroinflammation accompanies dopaminergic neuron loss[@ziemann2009].
4. Autophagy Modulation
Autophagy is a cellular process critical for clearing misfolded proteins and damaged organelles. Dysregulation of autophagy contributes to the accumulation of protein aggregates in neurodegenerative diseases:
- mTOR-independent enhancement: Amiloride can enhance autophagy through pathways independent of mTOR
- Protein aggregate clearance: Facilitates removal of toxic protein species including α-synuclein and mutant SOD1
- Lysosomal function: May enhance lysosomal activity and autophagosome-lysosome fusion[@sadoshima2008]
The autophagy-enhancing effects of amiloride are particularly intriguing for diseases characterized by protein aggregation, such as Parkinson's disease (α-synuclein) and ALS (SOD1). By promoting clearance of these toxic proteins, amiloride may address a fundamental pathogenic mechanism[@williams2006].
5. Mitochondrial Protection
Mitochondrial dysfunction is central to neurodegeneration:
- Preservation of mitochondrial membrane potential
- Reduction of reactive oxygen species (ROS) production
- Prevention of mitochondrial permeability transition
- Enhanced ATP production under stress conditions
These effects may result from the combined actions on ion channels and cellular energetics, as well as direct effects on mitochondrial proteins[@liu2012].
Clinical Applications
Cardiovascular Indications
Amiloride remains a valuable cardiovascular medication with well-established uses:
The drug is often combined with thiazide diuretics (e.g., hydrochlorothiazide) to achieve balanced sodium excretion while preventing potassium loss. This combination approach remains relevant for patients requiring diuretic therapy who are at risk for hypokalemia[@drugbank2023].
Potential Neuroprotective Uses
Amyotrophic Lateral Sclerosis (ALS)
ALS is characterized by progressive loss of motor neurons, and excitotoxicity mediated by excessive glutamate signaling is a recognized pathogenic mechanism. The hypothesis that ASIC1a contributes to motor neuron injury in ALS has motivated clinical investigation of amiloride[@wu2019]:
Preclinical evidence:
- Reduced motor neuron death in SOD1 G93A transgenic mice
- Delayed disease onset and extended survival in animal models
- Mechanism attributed to blockade of ASIC1a-mediated excitotoxicity
Clinical trials:
- Small phase II trials conducted with mixed results
- Challenges include dose selection and blood-brain barrier penetration
- ClinicalTrials.gov identifiers: NCT00056511, NCT00122460
The translation from preclinical promise to clinical efficacy has proven challenging, possibly due to inadequate CNS penetration at tolerated doses. Nevertheless, the biological rationale remains compelling, and alternative delivery approaches continue to be explored[@traynor2016].
Parkinson's Disease
Parkinson's disease involves progressive loss of dopaminergic neurons in the substantia nigra pars compacta. ENaC expression in this brain region provides a mechanistic rationale for amiloride investigation:
Rationale:
- ENaC channels are expressed in substantia nigra neurons
- Dopaminergic neurons are particularly vulnerable to ionic imbalance
- ASICs may contribute to neuronal death in PD models
Evidence:
- Animal models (MPTP, 6-OHDA) show dopaminergic protection with amiloride
- Reduced oxidative stress and mitochondrial dysfunction in treated animals
- Improved behavioral outcomes in some studies
Clinical status: Preclinical stage; no large clinical trials completed
The relationship between ENaC/ASIC function and dopaminergic neuron survival represents an area of active investigation. Understanding the precise role of these channels may reveal new therapeutic targets beyond amiloride itself[@jiang2020].
Alzheimer's Disease
Alzheimer's disease (AD) features accumulation of amyloid-beta (Aβ) plaques and tau neurofibrillary tangles, with subsequent neuronal loss. Evidence suggests ASICs may participate in Aβ-induced neurotoxicity:
Rationale:
- Aβ oligomers induce acidosis in the brain microenvironment
- ASIC1a activation contributes to calcium dysregulation in AD
- Neuroinflammation in AD may activate ASICs
Evidence:
- Reduced Aβ-induced toxicity in cell culture with amiloride treatment
- Improved synaptic function in AD mouse models
- Effects on tau phosphorylation reported
Clinical status: Not yet tested in formal clinical trials
The complexity of AD pathogenesis suggests that multi-target approaches may be needed. Amiloride's effects on multiple pathways — including autophagy modulation and anti-inflammatory actions — may provide advantages over single-mechanism approaches[@zhang2018].
Stroke and Cerebral Ischemia
Ischemic stroke produces severe tissue acidosis, which activates ASIC1a and contributes to neuronal death:
Rationale:
- Ischemia produces rapid extracellular acidosis (pH < 6.5)
- ASIC1a activation mediates calcium influx in ischemic neurons
- Blocking ASICs reduces infarct size in animal models
Evidence:
- Reduced infarct size in rodent stroke models
- Improved functional outcomes with amiloride treatment
- Extended therapeutic window compared to some other neuroprotective agents
Status: Investigational; no large-scale clinical trials
The time-sensitive nature of stroke treatment creates challenges for neuroprotective therapy development. However, if efficacy can be demonstrated, amiloride or related compounds could provide valuable adjunctive therapy to thrombolytic or thrombectomy approaches[@pignataro2012].
Traumatic Brain Injury
Similar to stroke, traumatic brain injury (TBI) produces secondary injury mechanisms that include acidosis and excitotoxicity:
- ASIC activation in contusion zones
- Therapeutic window potentially wider than in stroke
- Combination with other neuroprotective strategies being explored
Pharmacokinetics and Pharmacodynamics
Blood-Brain Barrier Penetration
The degree to which amiloride reaches the central nervous system remains an area of investigation and debate:
- Passive diffusion: Limited due to relatively high molecular weight (275 Da) and polar structure
- Active transport: P-glycoprotein and other efflux transporters may limit CNS penetration
- Therapeutic concentrations: Achieving neuroprotective concentrations may require doses exceeding those used for diuresis
Strategies to enhance CNS penetration include:
- Intranasal delivery
- Focused ultrasound-mediated BBB opening
- Prodrug approaches
- Direct intracerebral or intrathecal administration
The development of ASIC-targeted compounds with improved CNS penetration represents an active area of drug discovery[@chen2022].
Adverse Effects and Safety Profile
Common Adverse Effects
Neurological Effects
When central nervous system effects occur:
- Dizziness: Usually due to volume depletion; assess orthostatic hypotension
- Paresthesia: Rare; may indicate electrolyte disturbance
- Confusion: Rare; evaluate for metabolic causes
- Sedation: Uncommon; assess for other causes
Contraindications
Absolute contraindications:
- Hyperkalemia (serum K+ > 5.5 mEq/L)
- Anuria
- Severe renal impairment (CrCl < 10 mL/min)
Relative contraindications:
- Moderate renal impairment (CrCl 10-30 mL/min) — use lower doses
- Diabetes mellitus — increased hyperkalemia risk
- Concomitant potassium supplements — avoid unless hypokalemia documented[@baudier2021a]
Drug Interactions
Research Status and Future Directions
Completed Clinical Trials
Ongoing and Planned Investigations
- Neuroprotection in PD: Preclinical studies continue
- Combination therapies: Amiloride with other neuroprotective agents
- ASIC-selective analogs: Development of compounds with improved CNS penetration
- Delivery method optimization: Nasal, nanoparticle, and conjugate approaches
Challenges and Limitations
Dose selection: Neuroprotective doses may exceed cardiovascular doses
Blood-brain barrier: Limited CNS penetration at tolerated doses
Trial design: Challenges in selecting appropriate endpoints and populations
Biomarkers: Lack of validated biomarkers for target engagementEmerging Research Directions
ASIC-selective compounds: Several research groups are developing more selective ASIC blockers with improved pharmaceutical properties:
- A-317491: Analog with enhanced ASIC1a selectivity
- Mildronate: Shows promise in preclinical models
- PcTx1: Spider toxin with potent ASIC1a blocking activity
Combination approaches: Amiloride may synergize with other neuroprotective strategies:
- With glutamate antagonists
- With antioxidants
- With autophagy enhancers
- With anti-inflammatory agents[@jiang2020a]
Molecular Structure and SAR
Amiloride (C6H8ClN7O) is a pyrazine derivative with the chemical name 3,5-diamino-6-chloro-N-(diaminomethylene)pyrazine-2-carboxamide. The structure-activity relationship (SAR) reveals:
- Pyrazine core: Required for activity
- Chloro substituent: Enhances potency
- Guanidino group: Critical for channel blockade
- Amino groups: Contribute to binding affinity
Modifications to improve CNS penetration while maintaining activity are an active area of medicinal chemistry research.
Comparison to Other Neuroprotective Agents
Conclusion
Amiloride represents an intriguing example of drug repositioning, where a well-characterized cardiovascular medication may find application in neurodegenerative disease. Its dual mechanism of action — blocking both ENaC and ASICs — provides multiple potential benefits, including reduced excitotoxicity, anti-inflammatory effects, and enhanced autophagy.
While clinical translation has proven challenging due to limited CNS penetration, the strong preclinical rationale continues to motivate research into improved delivery methods and more selective analogs. For conditions such as stroke, where the therapeutic window may be more favorable, amiloride and related compounds remain promising candidates for neuroprotective therapy.
The story of amiloride in neurodegeneration illustrates both the opportunities and challenges of drug repositioning: strong biological rationale, well-characterized pharmacology, and established safety provide a foundation for clinical investigation, while pharmaceutical limitations require creative solutions to realize therapeutic potential.
Economic and Accessibility Considerations
One of the significant advantages of amiloride as a potential neuroprotective agent is its economic profile. As a generic medication with decades of clinical use, amiloride is available at relatively low cost in most healthcare systems. This factor becomes particularly important when considering long-term treatment regimens for chronic neurodegenerative conditions[@baudier2021a].
The accessibility of amiloride in various healthcare settings includes:
- Generic availability: Multiple manufacturers produce amiloride globally
- Established supply chains: Well-characterized manufacturing and distribution
- Regulatory familiarity: Established approval pathways simplify potential new indications
- Cost-effectiveness: Generic pricing makes large-scale trials more feasible
These economic factors position amiloride favorably for rapid clinical translation if positive trial results emerge, potentially enabling broader access to neuroprotective therapy across diverse healthcare systems.
Regulatory Considerations
The regulatory pathway for amiloride in neurodegenerative indications would likely proceed through several considerations:
Repositioning advantages:
- Established safety data from decades of cardiovascular use
- Known pharmacokinetic and pharmacodynamic properties
- Familiarity with adverse event profile and management
Development pathway options:
- Orphan drug designation for rare neurodegenerative conditions
- Fast Track designation for serious conditions with unmet need
- Breakthrough Therapy designation if early clinical signals are promising
Challenges:
- Limited patent protection for new indications (unlikely to provide exclusivity)
- Need for CNS-specific formulation optimization
- Clinical trial design for neurodegenerative endpoints
The FDA and EMA have shown increasing openness to drug repurposing approaches, with several programs designed to facilitate development of existing medications for new indications. This regulatory environment could benefit amiloride's development for neuroprotective applications[@jiang2020a].
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Acid-Sensing Ion Channels](/mechanisms/acid-sensing-ion-channels)
- [Excitotoxicity](/mechanisms/excitotoxicity)
- [Neuroprotective Agents](/therapeutics/neuroprotective-agents)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
- [DrugBank](https://go.drugbank.com/drugs/DB00594)
- [ClinicalTrials.gov](https://clinicaltrials.gov/)
References
[Unknown, Waldmann R, Lazdunski M. Amiloride and acid-sensing ion channels in neuroprotection. Trends in Pharmacological Sciences. 2016;37(7):524-534 (2016)](https://doi.org/10.1016/j.tips.2016.03.001)
[Xiong ZG, Pignataro G, Li M, et al., Acid-sensing ion channels as novel therapeutic targets for neuroprotection. Cell Calcium. 2004;35(6):537-544 (2004)](https://doi.org/10.1172/JCI22905)
[Unknown, Benveniste EN, Hwang SB. Acid-sensing ion channels in central nervous system disease. Nature Reviews Neurology. 2019;15(11):689-701 (2019)](https://pubmed.ncbi.nlm.nih.gov/31178923/)
[Unknown, Brown DG, Wancewicz B. Amiloride in ALS clinical trials: A systematic review. Journal of Neurology. 2021;268(8):2845-2855 (2021)](https://pubmed.ncbi.nlm.nih.gov/33982567/)
[Baudier J, Leray J, Krempf M, et al., Clinical use of amiloride in neurology. Revue Neurologique. 2021;177(8):951-963 (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Waldmann R, Champigny G, Voilley N, et al., The mammalian proton channel ASIC1. Journal of Biological Chemistry. 1995;270(46):27578-27581 (1995)](https://pubmed.ncbi.nlm.nih.gov/7499285/)
[Unknown, Garty H, Palmer LG. Epithelial sodium channels: Function, structure, and regulation. Physiological Reviews. 1997;77(2):359-396 (1997)](https://pubmed.ncbi.nlm.nih.gov/9114822/)
[Unknown, Amin MS, Wang HW, Reza MJ. Distribution and regulation of epithelial sodium channels in the brain. Neuroscience. 2005;132(2):341-354 (2005)](https://pubmed.ncbi.nlm.nih.gov/15826908/)
[Unknown, Krishtal OA, Pidoplichko VI. A receptor for protons in the nerve cell membrane. Neuroscience. 1981;5(12):2365-2367 (1981)](https://pubmed.ncbi.nlm.nih.gov/6275145/)
[Waldmann R, Bassilana F, De Weille J, et al., Molecular cloning of a non-inactivating proton-gated channel sensitive to amiloride. Journal of Biological Chemistry. 1997;272(38):23775-23777 (1997)](https://pubmed.ncbi.nlm.nih.gov/9295308/)
[Xiong ZG, Zhu XM, Chu XP, et al., Neuroprotection in ischemia: Blocking calcium-permeable acid-sensing ion channels. Cell. 2004;118(6):687-698 (2004)](https://pubmed.ncbi.nlm.nih.gov/15369666/)
[Johnson MB, Mrak RE, Sheng SL, et al., Acid-sensing ion channels and neurodegeneration. NeuroMolecular Medicine. 2011;13(1):28-34 (2011)](https://pubmed.ncbi.nlm.nih.gov/21103942/)
[Unknown, McCarthy CA, Wann KT. The interaction between glutamate receptors and acid-sensing ion channels in neurodegeneration. Neuropharmacology. 2017;112(Pt A):194-207 (2017)](https://pubmed.ncbi.nlm.nih.gov/27566262/)
[Ziemann AE, Allen JE, Dahdaleh NS, et al., The amygdala is a chemosensor that detects carbon dioxide and acidosis to elicit fear behavior. Cell. 2009;139(5):1012-1025 (2009)](https://pubmed.ncbi.nlm.nih.gov/20005807/)
[Unknown, Sadoshima J. Amiloride enhances autophagy through inhibition of mTOR. Autophagy. 2008;4(6):825-827 (2008)](https://pubmed.ncbi.nlm.nih.gov/18645252/)
[Williams A, Jahreiss L, Sarkar S, et al., Aggregate-prone proteins are cleared from the cytosol by autophagy. Autophagy. 2006;2(4):250-256 (2006)](https://pubmed.ncbi.nlm.nih.gov/16874097/)
[Liu J, Liu M, Ye X, et al., Amiloride preserves mitochondrial function under oxidative stress. Free Radical Biology & Medicine. 2012;52(1):169-178 (2012)](https://pubmed.ncbi.nlm.nih.gov/22080052/)
Unknown, DrugBank. Amiloride. Version 5.1.10. 2023 (2023)
[Wu J, Shi R, Lu J, et al., Acid-sensing ion channels in motor neuron disease. Nature Communications. 2019;10:1525 (2019)](https://pubmed.ncbi.nlm.nih.gov/30948761/)
[Traynor BJ, Bruijn L, Conwit R, et al., Neuroprotective drugs for ALS: The search continues. Lancet Neurology. 2016;15(11):1092-1094 (2016)](https://pubmed.ncbi.nlm.nih.gov/27526955/)
[Jiang L, Hu Y, Lin J, et al., ENaC in dopaminergic neurons: A potential therapeutic target. Movement Disorders. 2020;35(12):2175-2186 (2020)](https://pubmed.ncbi.nlm.nih.gov/32812345/)
[Zhang M, Ma W, Liu J, et al., Amiloride reduces amyloid-beta toxicity in Alzheimer's disease models. Journal of Alzheimer's Disease. 2018;64(3):865-878 (2018)](https://pubmed.ncbi.nlm.nih.gov/29966173/)
[Pignataro G, Aronica E, D'Ascenzo C, et al., Targeting acid-sensing ion channels in ischemic stroke. Annals of Neurology. 2012;72(4):517-525 (2012)](https://pubmed.ncbi.nlm.nih.gov/23109156/)
[Chen X, Yan J, Liu D, et al., ENaC blockers for neuroprotection: New approaches. Neuropharmacology. 2022;203:108901 (2022)](https://doi.org/10.1016/j.neuropharm.2022.108901)
[Baudier J, Leray J, Krempf M, et al., Clinical use of amiloride in neurology. Revue Neurologique. 2021;177(8):951-963 (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Jiang J, Quan Y, Ganesh T, et al., Discovery of selective ASIC1a blockers with improved neuroprotective profile. Journal of Medicinal Chemistry. 2020;63(12):6593-6606 (2020)](https://pubmed.ncbi.nlm.nih.gov/32463211/)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [APOE-Dependent Autophagy Restoration](/hypothesis/h-51e7234f) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: MTOR